Skip to main content Accessibility help
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 3 - Essential CNS drug development – pre-clinical development


Agid, Y., Buzsáki, G., and Diamond, D. M. (2007). How can drug discovery for psychiatric disorders be improved?Nat Rev Drug Discov, 6, 189–201.
Arguello, P. A. and Gogos, J. A. (2006). Modeling madness in mice: one piece at a time. Neuron, 52, 179–96.
Atkinson, A. J., Jr., Colburn, W. A., DeGruttola, V. G., et al. (2001). Clin Pharmacol Thera, 69, 89–95.
Babaoglu, K. and Shiochet, B. K. (2006). Deconstructing fragment based inhibitor discovery. Nat Chem Biol, 2, 720–33.
Berg, D. (2008). Biomarkers for the early detection of Parkinson's and Alzheimer's Disease. Neurodegen Dis, 5, 133–6.
Borsook, D., Bacerra, L., and Hargreaves, R. (2006). A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov, 5, 411–425.
Brekke, O. H. and Sandlie, I. (2003). Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov, 2, 52–62.
Cheng, A. C., Coleman, R. G., Smyth, K. T., et al. (2007). Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol, 25, 71–75.
Chico, L. K., Van Eldik, L. J., and Watterson, D. M. (2009). Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov, 8, 893–909.
Citron, M. (2010). Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov, 9, 387–98.
Edwards, P. D., Albert, J. S., Sylvester, M., et al. (2007). Application of fragment based lead generation to the discovery of novel cyclic amidine b-secretase inhibitors with nanomolar potency, cellular activity and high ligand efficiency. J Med Chem, 50, 5912–25.
Frank, R. and Hargreaves, R. (2003). Clinical markers in drug discovery and development. Nat Rev Drug Discov, 2, 566–80.
Gabrielsson, J., Dolgos, H., Gillberg, P.-G., et al. (2009). Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today, 14, 358–72.
Giakoumaki, S. G., Roussos, P., Rogdaki, M., et al. (2007). Evidence of disrupted prepulse inhibition in unaffected siblings of bipolar disorder patients. Biol Psychiat, 62, 1418–22.
Gottesman, I. I. and Gould, T.D. (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiat, 160, 636–45.
Gould, T. G. and Gottesman, I. I. (2006). Psychiatric endophenotypes and the development of valid animal models. Gene Brain Behav, 5, 113–19.
Gurwitz, D. (2002). Targeting Alzheimer's disease: is there a light at the end of the tunnel?Drug Dev Res, 56, 45–8.
Hall, J. E. (2002). The promise of translational physiology. Am J Physiol, L235–6.
Heilker, R., Wolff, M., Tautermann, C. S., et al. (2009). G-protein coupled receptor-focused drug discovery using a target class platform approach. Drug Discov Today, 5/6, 231–44.
Imming, P., Sinning, C., and Meyer, A. (2006). Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov, 5, 821–34.
Insel, T. R. and Cuthbert, B. N. (2009). Endophenotypes: bridging genomic complexity and disorder heterogeneity, Biol Psychiatry, 66 (11), 988–9.
Jagust, W. (2004). Molecular neuroimaging in Alzheimer's disease. NeuroRX, 1, 206–12.
Jorgensen, W. L. (2009). Efficient drug lead discovery and optimization. Accounts Chem Res, 42, 724–33.
Kato, M., Ikenaga, Y., Wakeno, M., et al. (2005). Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol, 20, 151–6.
Kiberstis, P. and Roberts, L. (2002). It's not just the genes. Science, 296, 685.
Knowles, J. and Gromo, G. (2003). Target selection in drug discovery. Nat Rev Drug Discov, 2, 63–9.
Krishnamurthy, H., Piscitelli, C. L., and Gouaux, E. (2009). Unlocking the molecular secrets of sodium-coupled transporters. Nature, 459, 347–55.
Le-Niculescu, H., Balaraman, Y., Patel, S., et al. (2007). Towards understanding the schizophrenia code: an expanded convergent functional genomics approach. Am J Med Genet, Neuropsychiatr Genet, 144B, 129–58.
Lesch, K. P. and Mossner, R. (1998). Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?Biol Psychiatry, 44, 179–92.
Light, G. A. and Braff, D. L. (1999). Human and animal studies of schizophrenia related gating deficits. Curr Psychiatr Rep, 1, 31–40.
Lindsay, M. A. (2003). Target discovery. Nat Rev Drug Discov, 2, 831–8.
Lipinski, C., Lombardo, F., Dominy, B., et al. (1997). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev, 23, 3–25.
Liu, X., Chen, C., and Smith, B. J. (2008). Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther, 325, 349–56.
Luddington, N. S., Mandadapu, A., Husk, M., et al. (2009). Clinical implications of genetic variation in the serotonin transporter promoter region: a review. Primary Care Companion J Clin Psychiatr, 11, 93–102.
Mancama, D. and Kerwin, R. W. (2003). Role of pharmacogenetics in individualising treatment with SSRIs. CNS Drugs, 17, 1–10.
Meyer-Lindenberg, A. and Weinberger, D. (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci, 7, 818–27.
Naatanen, R. and Kahkonen, S. (2009). Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int J Neuropsychopharmacol, 12, 125–35.
Overington, J. P., Al-Lazikani, B., and Hopkins, A. L. (2006). How many drug targets are there?Nat Rev Drug Discov, 5, 993–1002.
Pangalos, M. N., Schechter, L. E., and Hurko, O. (2007). Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat Rev Drug Discov, 6, 521–32.
Paolini, G. V., Shapland, R. H. B., van Hoorn, W. P., et al. (2006). Global mapping of pharmacological space. Nat Biotechnol, 24, 805–15.
Pavlou, A. K. and Reichert, J. M. (2004). Recombinant protein therapeutics success rates, market trends and values to 2010. Nat Biotechnol, 22, 1513–19.
Philipson, O., Lord, A., Gumucio, A., et al. (2010). Animal models of amyloid-b-related pathologies in Alzheimers disease. FEBS J, 277, 1389–409.
Phillips, M. L. and Vieta, E. (2007). Identifying functional neuroimaging biomarkers of bipolar disorders: Towards DSM-V. Schizophrenia Bull, 33, 893–904.
Quinones, M. P. and Kaddurah-Daouk, R. (2009). Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis, 35, 165–176.
Rosas, H. D., Feigin, H. S., and Hersch, S. M. (2004). Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRX, 1, 263–272.
Sarter, M. (2006). Preclinical research into cognition enhancers. Trends Pharmacol Sci, 27, 602–8.
Schmidtke, P. and Barril, X. (2010). Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J Med Chem, 53, 5858–67.
Spedding, M., Jay, T., Costa, J., et al. (2005). A pathophysiological paradigm for the therapy of psychiatric disease. Nat Rev Drug Discov, 4, 467–76.
Spigset, O. and Martensson, B. (1999). Fortnightly review: drug treatment of depression. Brit Med J, 318, 1188–91.
Sunderland, T., Linker, G., Nadeem, M., et al. (2003). Decreased β-amyloid 1–42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer's disease. J Am Med Assoc, 289, 2094–103.
Swerdlow, N. R., Weber, M., Qu, Y., et al. (2008). Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology, 199, 331–88.
Tan, H. Y., Callicott, J. H., and Weinberger, D. R. (2008). Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?Mol Psychiatry, 13, 233–8.
Whiting, P. (2003). GABA-A receptor subtypes in the brain: a paradigm for drug discovery?Drug Discov Today, 8, 445–52.
Wu, G. and Doberstein, S. K. (2006). HTS technologies in biopharmaceutical discovery. Drug Discov Today, 11, 718–26.
Wulff, H., Castle, N. A., and Pardo, L. A. (2009). Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov, 8, 98–1001.
Zimmermann, G. R., Lehar, J., and Keith, C. T. (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today, 12, 34–42.